HPV Vaccine’s Impact on Cervical Cancer Deaths in the UK

A recent review of the HPV vaccine demonstrates that, in the UK, the risk of dying from cervical cancer before age 30 has dropped to nearly zero. This finding, published in The Lancet medical journal, has sparked optimism among health experts and countries implementing similar vaccination programs.

Cervical cancer is known for its aggressive nature, often striking young women under 30, making these results particularly significant. HPV, primarily transmitted through sexual contact, is the leading cause of cervical cancer. In the UK, routine vaccinations for both girls and boys started in 2008.

Recent Study Findings

Conducted by Queen Mary University of London and funded by Cancer Research UK, this study reveals that from 2020 to 2024, no women aged 20 to 24 died from cervical cancer in the UK. Prior to the vaccine, it was estimated that 23 deaths might have occurred in that age group during this period.

Looking back, 25 deaths were reported from 2000 to 2004, followed by 16 from 2005 to 2009, and later 27 from 2010 to 2014. By 2015 to 2019, the number decreased to five.

Michelle Mitchell, the chief executive of Cancer Research UK, expressed excitement about these findings, highlighting that the vaccine effectively prevents cervical cancer and, as shown for the first time, saves lives.

Understanding HPV

The World Health Organization (WHO) describes HPV as a group of over 200 related viruses, most commonly spread through sexual contact. It often enters the body via skin-to-skin contact, which may happen unnoticed. While many sexually active individuals may contract HPV, symptoms usually appear as genital warts, linked to low-risk types of the virus. Fortunately, about 90% of people clear the virus naturally within two years.

HPV and Cancer

Certain high-risk strains of HPV are persistent and can lead to several types of cancer, including cervical cancer, as well as other cancers affecting the genital and throat areas. Vaccination is viewed as the best method to prevent these high-risk infections and their associated cancers. Although no treatment exists to eliminate the virus itself, various treatments can address related symptoms and conditions.

The prevalence of HPV and related cancers is alarming:

• HPV was estimated to cause approximately 620,000 new cancer cases in women and 70,000 in men globally in 2019.
• According to the WHO, more than 95% of the 660,000 cases of cervical cancer each year are linked to HPV.
• Cervical cancer ranks as the fourth most common cancer among women worldwide, with roughly 660,000 new cases and 350,000 fatalities reported in 2022.
• The average five-year survival rate after diagnosis is about 67%, but this figure varies; early-stage diagnoses significantly improve survival chances.
• About 94% of cervical cancer-related deaths occur in low and middle-income countries.

How HPV Leads to Cervical Cancer

Cervical cancer generally arises several years after an HPV infection. If the immune system struggles to eliminate the virus, it can disrupt normal cell growth, resulting in abnormal cells that may develop into a precancerous state. If left untreated, this can progress to cancer. Consequently, women aged 30 to 65 are recommended to undergo regular cervical screenings.

Cervical Cancer Death Rates by Country

Death rates from cervical cancer are particularly high in low and middle-income nations, with regions such as sub-Saharan Africa, Central America, and Southeast Asia most affected. In 2022, India reported 79,906 cervical cancer deaths, while China and Indonesia faced 55,694 and 20,708 fatalities, respectively.

Presently, 28 out of Africa’s 54 nations have incorporated the HPV vaccine into their national vaccination programs, but only five have achieved the ambitious 90% coverage goal set for 2030. In early 2023, India initiated a free HPV vaccination program for 11.5 million girls aged 14, utilizing the Gardasil vaccine.

China introduced its HPV vaccine into its national program in October 2025, offering two free doses to eligible girls. Pakistan also launched its inaugural national HPV vaccine campaign around the same time, targeting over 13 million girls with a complimentary vaccine. Cervical cancer claims eight lives each day in Pakistan, emphasizing the urgency of these efforts. Indonesia has similarly begun offering HPV vaccinations for girls as part of its national immunization initiative.

Challenges Faced by HPV Vaccination Programs

Like other vaccines, the HPV vaccine faces hesitancy in various parts of the world. In the West, some still believe in unfounded links between vaccines and conditions such as autism, despite no scientific support for these claims. In conservative cultures, the sexually transmitted nature of HPV raises questions about the vaccine’s necessity.

Misinformation and conspiracy theories also circulate, alleging that the HPV vaccine may lead to infertility, another claim without evidence. A 2020 study indicated no heightened risk of infertility among vaccinated women.

In Pakistan, obstacles have hindered the vaccine initiative’s success, further complicated by historical events that contributed to skepticism regarding vaccination campaigns. The challenge of vaccine hesitancy, coupled with societal attitudes towards HPV, continues to pose significant hurdles for these vital health programs.